Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9
Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
Authors Chen L, Ascher-Svanum H, Lawson, Stauffer, Nyhuis, Haynes VS, Schuh , Kinon B
Received 2 February 2013
Accepted for publication 26 April 2013
Published 14 June 2013 Volume 2013:9 Pages 815—822
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Lei Chen, Haya Ascher-Svanum, Anthony Lawson, Virginia L Stauffer, Allen Nyhuis, Virginia Haynes, Kory Schuh, Bruce J Kinon
Eli Lilly and Company, Indianapolis, IN, USA
Background: This study identified subgroups of patients with schizophrenia who differed on their movement disorder profile and compared their treatment outcomes.
Methods: Data from a randomized, open-label, one-year study of patients with schizophrenia who were treated with antipsychotics in usual clinical care settings were analyzed (n = 640). Five measures of movement disorder were incorporated into a single Movement Disorder Index (MDI). Subgroups that differed in their movement disorder profile over the one-year study period were compared on clinical and functional outcomes.
Results: Three subgroups were identified: a worsening of MDI in 15% of patients, an improvement in 33%, and no change in 53%. Compared with the other two subgroups, the MDI-worsened subgroup had poorer symptom improvement measured by the Positive and Negative Syndrome Scale (PANSS) total score (mean changes of −11.0, −18.4, and −16.8 for the patients who had a worsening of MDI, no change, and an improvement, respectively), poorer symptom improvement on the PANSS positive and anxiety/depression subscale scores, worsening on the 36-Item Short Form Health Survey (SF-36) physical component summary score, and a higher rate of hospitalization (P < 0.05).
Conclusion: Patients with schizophrenia who experience worsening of their MDI score appear to have poorer clinical and functional outcomes, suggesting that such worsening may be a marker of poorer prognosis.
Keywords: schizophrenia, treatment outcome, movement disorder
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.